ProCE Banner Activity

CME

Optimal Therapeutic Sequencing in Relapsed/Refractory CLL

Video

In this on-demand webcast, experts discuss the strategic management of relapsed and refractory chronic lymphocytic leukemia (CLL). During the discussion, there will be an emphasis on the importance of personalized, evidence-based sequencing of therapies to maximize treatment efficacy and improve patient outcomes.

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: November 27, 2024

Expiration: May 26, 2025

Share

Faculty

Othman Al-Sawaf

Othman Al-Sawaf, MD

Hematologist & Medical Oncologist
Principal Investigator
University Hospital of Cologne
German CLL Study Group
Cologne, Germany

Farrukh T. Awan

Farrukh T. Awan, MD, MS, MBA

Associate Director, Section of Hematologic Malignancies/Transplantation and Cellular Therapy
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Alessandra Tedeschi

Alessandra Tedeschi, MD

Consultant in Hematology
Division of Hematology
Niguarda Hospital
Milano, Italy

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Target Audience

This activity is intended for hematologists, oncologists, and other healthcare professionals globally who care for patients with chronic lymphocytic leukemia.

Program Learning Goal

This activity claims to improve learners' knowledge, competence, and performance to optimize clinical outcomes for patients with chronic lymphocytic leukemia.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Integrate new and emerging data on noncovalent BTK inhibitors into the management of patients with relapsed/refractory CLL/SLL

  • Plan therapeutic strategies for patients with relapsed/refractory CLL/SLL based on current guidelines, available clinical evidence, and expert recommendations

  • Proactively select and sequence treatment regimens and long-term treatment plans for individual patients with CLL/SLL to optimize clinical benefit

  • Assess patients with relapsed/refractory CLL/SLL who have progressed on or following covalent BTK inhibitor therapy for resistance mutations

  • Implement effective interprofessional team processes and workflows to promote adherence to and persistence with oral anticancer therapy to ensure optimal clinical outcomes in patients with relapsed/refractory CLL/SLL

  • Mitigate and manage treatment-related and disease-related adverse events in patients with relapsed/refractory CLL/SLL

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Othman Al-Sawaf, MD

Hematologist & Medical Oncologist
Principal Investigator
University Hospital of Cologne
German CLL Study Group
Cologne, Germany

Othman Al-Sawaf, MD: consultant/advisor/speaker: AbbVie, Adaptive, AstraZeneca, BeiGene, Gilead, Janssen, Lilly, Roche; researcher: AbbVie, BeiGene, Janssen, Roche.

Farrukh T. Awan, MD, MS, MBA

Associate Director, Section of Hematologic Malignancies/Transplantation and Cellular Therapy
Director of Lymphoid Malignancies Program
Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Farrukh T. Awan, MD, MS, MBA: consultant/advisor/speaker: AbbVie, Adaptive Biotechnologies, ADCT Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Caribou Biosciences, Dava Oncology, Genmab, Incyte, Kite, Loxo Oncology; researcher: AbbVie/Pharmacylcis.

Alessandra Tedeschi, MD

Consultant in Hematology
Division of Hematology
Niguarda Hospital
Milano, Italy

Alessandra Tedeschi, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Johnson & Johnson, Lilly.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 27, 2024, through May 26, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.